Raymond James Maintains Outperform on LianBio, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Dane Leone has maintained an 'Outperform' rating on LianBio (NASDAQ:LIAN), but lowered the price target from $15 to $9.

October 25, 2023 | 9:09 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Raymond James has maintained an 'Outperform' rating on LianBio, but lowered the price target from $15 to $9.
The news is directly related to LianBio and is likely to impact its stock price. While the 'Outperform' rating is positive, the lowering of the price target may have a negative effect. However, it's hard to predict the exact short-term impact on the stock price, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100